Bevacizumab maintenance in metastatic colorectal cancer: How long?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

394

WORD

252

HTML

2482

Figures (1-7)

246

Sum=3374

Publishing Process of This Article

Item

Count

Browse

1043

Download

1393

Sum=2436

Nov 16, 2014 (publication date) through Nov 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Nov 16, 2014; 2(11): 717-723
Published online Nov 16, 2014. doi: 10.12998/wjcc.v2.i11.717

Full Size Figure Download Figure

Figure 6 CEA (ng/mL) and CA19. 9 (U/mL) serum levels throughout the treatment and follow-up period.

Citation: Stefano AD, Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Pietro FD, Pepe S, Placido SD, Carlomagno C. Bevacizumab maintenance in metastatic colorectal cancer: How long? World J Clin Cases 2014; 2(11): 717-723
URL: https://www.wjgnet.com/2307-8960/full/v2/i11/717.htm
DOI: https://dx.doi.org/10.12998/wjcc.v2.i11.717